Results 51 to 60 of about 53,966 (229)

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma

iScience, 2023
Summary: Drug resistance prominently hampers the effects of systemic therapy of sorafenib to hepatocellular carcinoma (HCC). Epigenetics have critical regulatory roles in drug resistance.
Shanshan Wang, Xin You, Xiaoshu Liu, Fengwei Zhang, Hongjuan Zhou, Xuechai Shang, Long Cai   +6 more
doaj   +1 more source

Artesunate Ameliorates APAP‐induced Liver Injury by Promoting NEDD4L‐Mediated Ubiquitination and Degradation of TXNIP

Advanced Science, EarlyView.
ABSTRACT Liver injury can lead to severe acute liver failure and even death in patients. Artesunate (ART), which is a derivative of artemisinin that has been approved by the FDA for the treatment of malaria, has significant regulatory effects on cell death and inflammation.
Zhe Zhang, Hongyi Zhang, Haixiang Guo, Xiwen Zhang, Yidan Wang, Baoyin Wang, Tong Wang, Guokun Zhao, Qing Zhang, Fei Gao, Shuang Liang, Hao Jiang, Yu Ding, Xiliang Du, Jiabao Zhang, Yi Zheng, Xinwei Li, Bao Yuan   +17 more
wiley   +1 more source

PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Liver Cancer, 2023
Introduction Intratumoral administration of pexa-vec (Pexastimogene Devacirepvec), an oncolytic and immunotherapeutic vaccinia virus. given to patients with hepatocellular carcinoma (HCC), is associated with both local and distant tumor responses.
Ghassan K. Abou-Alfa, Peter R. Galle, Yee Chao, Joseph Erinjeri, Jeong Heo, Mitesh J. Borad, Angelo Luca, James Burke, Adina Pelusio, Delphine Agathon, Monika Lusky, Caroline Breitbach, Shukui Qin, Edward Gane   +13 more
doaj   +1 more source

CircRSU1 Activates the hnRNPA1/HIF‐1α/CD24 Signaling Axis, Promoting Stemness Features of Hepatocellular Carcinoma

Advanced Science, EarlyView.
This study reveals circRSU1 with important oncogenic roles in hepatocellular carcinoma (HCC). CircRSU1, highly abundant in HCC, interacts with and stabilizes hnRNPA1 from ubiquitination and degradation. This stabilization facilitates hnRNPA1 binding to the internal ribosome entry site of HIF1A to increase HIF‐1α protein translation.
Shuting Xue, Danduo Wei, Yongzhi Zhao, Jinchang Pan, Hanyuan Zhang, Niya Liu, Jianjuan Zhang, Jiaxin Liu, Jianping Jin, Mu Xiao, Xinhua Feng, Aifu Lin, Lei Zhao, Stephanie Roessler, Junfang Ji   +14 more
wiley   +1 more source

The Monoclonal Antibody CH12 Enhances the Sorafenib-Mediated Growth Inhibition of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III

Neoplasia: An International Journal for Oncology Research, 2012
The multikinase inhibitor sorafenib is the first oral agent to show activity against human hepatocellular carcinoma (HCC). Although the clinical application of sorafenib has shown good tolerability in the studied populations, it also causes multiple ...
Yaqiong Yang, Hua Jiang, Huiping Gao, Juan Kong, Pengwei Zhang, Suwen Hu, Bizhi Shi, Pengfei Zhang, Ming Yao, Zonghai Li   +9 more
doaj   +1 more source

Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. [PDF]

PLoS ONE, 2016
Treatment outcomes of sorafenib therapy may greatly vary depending not only on tumor spread but also on past clinical processes prior to sorafenib therapy and timing of sorafenib administration in the past clinical course of hepatocellular carcinoma (HCC)
Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Eiichiro Suzuki, Masanori Inoue, Toru Wakamatsu, Akinobu Tawada, Osamu Yokosuka   +7 more
doaj   +1 more source

Nanozymes for Liver Disease Therapy: Advances in Catalytic Activity, Targeting Strategies, and Clinical Translation

Advanced Science, EarlyView.
Nanozymes, as enzyme‐mimicking nanomaterials, exhibit unique catalytic properties for the treatment of liver diseases. By regulating redox homeostasis, modulating immune responses, and enabling targeted delivery, nanozymes overcome the limitations of natural enzymes.
Xiandi Meng, Ge Zhu, Siyu Sun, Wenbo Yao, Yuning Zhang, Yong‐Guang Yang, Tianmeng Sun   +6 more
wiley   +1 more source

Ferroptosis Induction by Fenbendazole Combined With Photothermal Therapy Triggers Dual‐Immunotherapy Against Bladder Cancer

Advanced Science, EarlyView.
The novel intravesical delivery system exhibits GSH‐responsive drug release, enabling a synergistic therapeutic strategy that combines ferroptosis, ICD and PTT. ABSTRACT Ferroptosis, a newly recognized form of regulated cell death, has emerged as a promising strategy in cancer therapy.
Xiaojian Xu, Rui Liang, Anguo Zhao, Jun Zhang, Rongkang Li, Yang Liu, Dashi Deng, Qi Zhuang, Lisha Liu, Lei Peng, Miao Li, Xuedong Wei, Yuhua Huang, Shaohua Zhang, Liang Cheng, Jianquan Hou   +15 more
wiley   +1 more source

High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo

BMC Cancer, 2017
Background Primary liver cancer is a lethal malignancy with a high mortality worldwide. Currently, sorafenib is the most effective molecular-targeted drug against hepatocellular carcinoma (HCC). However, the sorafenib resistance rate is high.
Yinzong Xiao, Lunquan Sun, Yongming Fu, Yan Huang, Rongrong Zhou, Xingwang Hu, Pengcheng Zhou, Jun Quan, Ning Li, Xue-Gong Fan   +9 more
doaj   +1 more source

Association of HAMP Expression and CD8+ T‐Cell Infiltration With Atezolizumab–Bevacizumab Response in Hepatocellular Carcinoma

Annals of Gastroenterological Surgery, EarlyView.
In hepatocellular carcinoma treated with atezolizumab–bevacizumab, responders showed RNA‐seq enrichment of immune and chemokine pathways with higher HAMP expression. In resected specimens, immunohistochemistry confirmed increased intratumoral CD8+ T‐cell density and hepcidin (HAMP), supporting HAMP plus CD8 as components of a composite predictor of ...
Shun Nakamura, Yuki Murakami, Yusuke Oshima, Takashi Masuda, Wataru Miyoshino, Hiroomi Takayama, Yoko Kawano, Teijiro Hirashita, Yuichi Endo, Masafumi Inomata   +9 more
wiley   +1 more source